Skip to content

Cbio A/S, a developer of T-cell therapies, presents its 2023 annual report as part of preparations for clinical trials and announces the transition to the clinical phase with secured funding of DKK 40 million.

SØBORG, Denmark, April 15, 2024 (GLOBE NEWSWIRE) — Cbio A/S – A pioneer in next-generation T-cell therapies for solid tumors, announces financial results for 2023 and recent company updates.

Cbio A/S, a developer of T-cell therapies, presents its 2023 annual report as part of preparations for clinical trials and announces the transition to the clinical phase with secured funding of DKK 40 million.
author avatar
LabNews Media LLC
The Editors in Chief of labnews.ai are Marita Vollborn and Vlad Georgescu. They are bestselling authors, science writers and science journalists since 1994.More details about their writing on X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu
LabNews Media LLC

LabNews Media LLC

The Editors in Chief of labnews.ai are Marita Vollborn and Vlad Georgescu. They have been bestselling authors, science writers, and science journalists since 1994.More details about their writing at X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu